Immunophotonics co-founders Lu Alleruzzo (CEO), Tomas Hode, PhD (CIO and President), and David Anderson, PhD (CSO) are excited to be attending CIRSE 2024 Congress taking place in Lisbon, Portugal, September 14th to 18th and ESMO Congress in Barcelona, Spain on September 16th. They look forward to engaging with fellow professionals, discussing the latest advancement in interventional oncology.
Be sure to visit Immunophotonics’ Booth 60 at the CIRSE Congress to discover how Immunophotonics is pioneering the novel approach of having interventional radiologists take a routine tumor-ablation procedure and “Abscopalize It®” through the concurrent injection of an immunoadjuvant. Don’t miss this opportunity to be a part of a conversation that could shape the future of interventional oncology.
